A Phase III Double Blind Randomized Placebo Controlled Study of Trastuzumab as Short Duration Preoperative Therapy in Patients With HER2-neu Positive Operable Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 24 Apr 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Apr 2020.
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2013 Actual initiation date changed from Feb 2013 to May 2013 as reported by ClinicalTrials.gov.